Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Economic Impact of Antimicrobial Resistance
John E. McGowan
Table 1
Different perspectives of economic impact of antimicrobial-drug resistancea
| Health-care | Drug | Public | |||
|---|---|---|---|---|---|
| Physician | Patient | business | industry | ("society") | |
| Focus | Individual | Individual | Care group | Potential clients | Population |
| Outcome | Absence of disease | Absence of disease | Reduce cost of care | Product sales | Maximize health |
| Time frame | Short | Short | Short | Short, long | Long |
| Motivation | Professionalism | Personal well-being | Profit | Profit | Social good |
| Approach | Treatment | Treatment | Cost containment | Develop new drugs, maintain life of old drugs | Reduce forces leading to resistance |
aCordell RL, Solomon SL, Scott RD, McGowan JE Jr, unpub. data.
Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."
Page created: May 10, 2011
Page updated: May 10, 2011
Page reviewed: May 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.